Advertisement
Document › Details
iTeos Therapeutics S.A.. (1/30/20). "Press Release: iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region". Gosselies & Cambridge, MA.
Region | Wallonia (region) | |
Country | Belgium | |
Organisation | iTeos Therapeutics S.A. | |
Group | iTeos Therapeutics (Group) | |
Organisation 2 | Wallonia (govt region) | |
Product | EOS100850 (adenosine A2A antagonist, iTeos Therapeutics) | |
Product 2 | EOS884448 (anti-TIGIT antibody, iTeos Therapeutics) | |
Index term | iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €11.5m for ph1b/2a of EOS-850 from Walloon Region | |
Index term 2 | iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €3.5m for ph1 of EOS-448 from Walloon Region | |
Person | Borsus, WIlly (Wallonia (govt) 202001 Minister of Economy + Research) | |
Person 2 | Detheux, Michel (iTeos Therapeutics 201205 CEO + Co-founder) | |
Funds will be used to progress iTeos’ two highly innovative clinical-stage oncology programs: a best-in class A2A receptor antagonist and an ADCC-enabled anti-TIGIT antibody drug candidate
iTeos Therapeutics SA, a privately-held biotechnology company developing innovative cancer immunotherapies, today announced that it has been awarded a total of €15 million in non-dilutive funding to support the clinical development of its two proprietary anti-cancer drug programs, targeting key mechanisms of immunosuppression that are gaining prominence within industry development pipelines. The funding has been approved on behalf of the Walloon Region by Willy Borsus, Minister of Economy and Research.
Funding of €11.5 million has been awarded to progress iTeos’ lead candidate EOS-850, a best-in-class adenosine A2A receptor antagonist, and will be used to support the ongoing phase 1b/2a clinical trial, underway at four sites across Europe, and will soon expand to clinical sites in the United States. A second award of €3.5 million will support the Phase 1 clinical trial of iTeos’ fully-human ADCC-enabled anti-TIGIT antibody (EOS-448), which is expected to start in Belgium in February 2020.
Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented, “We are grateful to the Walloon Region for its continued support of iTeos Therapeutics. This investment is invaluable as we seek to progress our two clinical programs. During the last three years, iTeos has developed a comprehensive portfolio of immuno-oncology drug candidates, and these additional Walloon region funds will help us evaluate the performance of our promising lead programs in the clinic.”
For further information, please contact:
Michel Detheux, CEO
iTeos Therapeutics
info@iteostherapeutics.com
Amber Fennell, Catherine Day, Matthew Neal and Sukaina Virji
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com
Sarah McCabe
Stern Investor Relations, Inc.
+1 212 362 1200
sarah.mccabe@sternir.com
Record changed: 2023-06-05 |
Advertisement
More documents for iTeos Therapeutics (Group)
- [1] Ona Therapeutics. (12/2/21). "Press Release: Ona Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors". Barcelona....
- [2] iTeos Therapeutics Inc.. (6/14/21). "Press Release: iTeos Therapeutics and GSK Announce Development and Commercialisation Collaboration for EOS-448, an anti-TIGIT Monoclonal Antibody, Enabling Novel Next-generation Immuno-oncology Combinations". Gosselie...
- [3] iTeos Therapeutics Inc.. (7/23/20). "Press Release: iTeos Therapeutics Announces Pricing of Initial Public Offering". Cambridge, MA & Gosselies....
- [4] iTeos Therapeutics Inc.. (6/9/20). "Press Release: iTeos Therapeutics Strengthens Leadership Team. Matthew Gall Joins as Chief Financial Officer". Cambridge, MA & Gosselies....
- [5] iTeos Therapeutics Inc.. (4/1/20). "Press Release: iTeos Therapeutics Closes $125 Million Series B2 Financing". Cambridge, MA & Gosselies....
- [6] iTeos Therapeutics S.A.. (2/27/20). "Press Release: iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers". Cambridge, MA & Gosselies....
- [7] iTeos Therapeutics S.A.. (12/12/19). "Press Release: iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with Keytruda". Gosselies & Cambridge, MA....
- [8] iTeos Therapeutics S.A.. (8/13/19). "Press Release: iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer". Gosselies & Cambridge, MA....
- [9] iTeos Therapeutics S.A.. (7/3/18). "Press Release: iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer". Gosselies....
- [10] iTeos Therapeutics S.A.. (6/27/18). "Press Release: iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director". Gosselies....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top